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was developed in UK English (Speight and Bradley; 2001) and most recently updated 
in 2008 in consultation with UK diabetologists, a diabetes specialist nurse (DSN), a 
dietician, and a podiatrist. A conceptual deﬁnition of each item was provided by the 
developer, forward translations were produced in Germany and Spain. Results of the 
ﬁrst translations and questions were discussed with the developer and a diabetologist, 
DSN, dietician and the translation team in each country. The initial UK version was 
revised. The German and Spanish versions were back translated into UK English and 
tested for acceptability and comprehension during cognitive debrieﬁng interviews with 
eight people with diabetes in each country, before ﬁnal language versions were estab-
lished. RESULTS: First results obtained after the forward translation and discussion 
in Spain and Germany showed that diabetes management differs somewhat across 
countries and differences in dietary habits and alcohol use necessitated some adapta-
tion to the questions. The establishment of a harmonized questionnaire required some 
rewording of items and reordering. Challenges encountered, including those concern-
ing diet and alcohol, and how these were dealt with during all steps of the process 
will be described in the presentation. CONCLUSIONS: An internationally acceptable 
version of the ADKnowl was developed following a rigorous methodology to facilitate 
international comparison and pooling of data. This project demonstrates the impor-
tance of assessing the suitability of the item content of a knowledge measure to the 
clinical and cultural context of the target countries.
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THE IMPACT OF STARTING INSULIN GLARGINE VERSUS INSULIN 
DETEMIR ON QUALITY OF LIFE (QOL) AND TREATMENT 
SATISFACTION (TS) IN PATIENTS WITH TYPE 2 DIABETES 
INADEQUATELY CONTROLLED ON ORAL GLUCOSE-LOWERING 
DRUGS (OGLDS)
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OBJECTIVES: To compare the impact of starting either insulin glargine once-daily 
or insulin detemir twice-daily on multiple dimensions of QOL in patients with type 
2 diabetes inadequately controlled on OGLDs. METHODS: This study was part of 
a 24-week, multinational, randomised trial in which 964 insulin-naïve patients, 
aged 40–75 years, with inadequately controlled type 2 diabetes (HbA1c 7.0–10.5%) 
were randomised to glargine once-daily or detemir twice-daily. For both insulins the 
dose was titrated every 2 days by 2 U to obtain fasting plasma glucose 5.6 mmol/l. 
For detemir, there also was a pre-dinner target 5.6 mmol/l. QOL and TS were 
assessed using: type 2 Diabetes Symptom Checklist revised (DSC-r), World Health 
Organization-5 well-being index (WHO-5), Hypoglycaemia Fear Survey (HFS) and 
Diabetes Treatment Satisfaction Questionnaire (DTSQ). Higher scores indicate greater 
symptom distress, well-being, worries about hypoglycaemia and TS, respectively. 
Data were analysed using ANCOVA. RESULTS: HbA1c reductions and overall 
hypoglycaemia were comparable between glargine and detemir (mean o SD change in 
HbA1c: 1.46 o 1.09 and 1.54 o 1.11%, respectively [P  0.149]). Total diabetes-
related symptom distress (DSC-r) decreased in both treatment groups. There were 
no signiﬁcant differences between groups, except for the neuropathic pain subscale 
(P  0.027 in favour of glargine). Well-being (WHO-5) increased equally in both 
groups (6.13 o 21.47 for glargine and 7.54 o 19.06 for detemir on scale 0–100, P 
 0.742). There was no signiﬁcant difference between treatments for the HFS (P  
0.441). TS (DTSQ) improved for both treatment groups, but signiﬁcantly more for 
glargine than for detemir: Mean o SD increase in total satisfaction score (scale 0–36): 
5.1 o 8.6 for glargine and 4.1 o 8.8 for detemir (P  0.001). CONCLUSIONS: Initiat-
ing glargine once-daily or detemir twice-daily in patients with type 2 diabetes failing 
OGLDs resulted in similarly improved glycaemic control, associated with an overall 
positive effect on diabetes symptom distress and emotional well-being. TS improved 
with both insulins, however, improvement was signiﬁcantly greater with glargine 
than detemir.
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COMPARING THE IMPACT OF DEPRESSION, DIABETES, AND ANXIETY 
ON PATIENT PRODUCTIVITY AND QUALITY OF LIFE: RESULTS FROM 
A NATIONALLY REPRESENTATIVE PANEL DATA
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OBJECTIVES: This study aims to estimate and compare quality of life and productiv-
ity loss among three chronic and prevalent conditions. METHODS: Retrospective 
secondary database analysis using Medical Expenditure Panel Survey data from years 
2000–2003 was conducted. Patients identiﬁed using the 3-digit ICD-9 codes: diabe-
tes(250) depression(311) and anxiety(300). QOL was measured using EQ-5D & pro-
ductivity measured using absenteeism data. RESULTS: A total of 12,858 patients were 
identiﬁed, 11% of patients had two or more of the conditions studied. About 17% 
of diabetes patients had an EQ-5D index score of 0.30, compared to 20% each on 
depression and anxiety. All 3 conditions had signiﬁcant impact on patient’s overall 
QOL (p  0.001). Mean EQ 5D index for diabetes was 0.65 (95% CI 0.64–0.66), 
depression—0.62 (95% CI 0.61–0.63), and anxiety—0.62 (95% CI 0.61–0.64). More 
number of patients with depression and anxiety missed work (21%) and stayed in bed 
(17%) due to illness compared to diabetes patients (12% and 9% respectively), but 
the mean days diabetes patients missed work was higher—12.15 (95% CI 10.38–
13.92) compared to anxiety—9.39 (95% CI 7.8–10.89) and depression—8.88 (95% 
CI 7.79–9.96) CONCLUSIONS: All three conditions were found to have a signiﬁcant 
negative impact on patient’s QoL and productivity. Our research indicates that anxiety 
and depression inﬂict similar disease burden compared to diabetes on patient. Future 
research should focus on reducing this burden.
DIABETES/ENDOCRINE DISORDERS – Health Care Use & Policy Studies
PDB58
THE “WHO, HOW AND THEN WHAT . . .” OF INSULIN INITIATION IN 
UK PRIMARY CARE
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1Eli Lilly and Company, Surrey, UK, 2CSD EPIC, London, UK
OBJECTIVES: To understand how insulin is initiated, describe patients with type 2 
diabetes (T2DM) initiating insulin in UK primary care, and look at changes in therapy, 
clinical outcomes and contact with health care professionals (HCPs) after insulin ini-
tiation. METHODS: Patients aged q18 years with a code for T2DM initiating insulin 
(baseline) from May 2004 to May 2006 were identiﬁed in the THIN database. Patient 
characteristics, clinical measures, treatment and contact with HCPs were collected at 
baseline and during 6 months follow-up. RESULTS: A total of 4045 patients met the 
inclusion criteria, 56% were male. Patient characteristics at baseline [mean (SD)] were; 
age: 62.6(13.3) years, BMI: 30.2(6.5) kg/m2 and HbA1c: 9.6%(2.0%). The most preva-
lent co-morbidities were hypertension (63%), coronary heart disease (26%), hyperli-
paedemia (24%), and depression (22%). 97.4% of patients had contact with their 
GP-surgery in the 6 months before insulin initiation, mean 7.1 contacts; 78.1% were 
referred to secondary care; and 18% were hospitalised. In the 12 months prior to 
insulin initiation 8.5% of patients had no prescriptions for oral antidiabetic medica-
tions (OAD), 13.4% for a single OAD class and 78.1% for q2 different OAD classes. 
52.4% of patients initiated intermediate/long acting insulin therapy only, a further 
41.6% pre-mix insulin only and the remainder initiated basal bolus (4.0%) or fast 
acting only (2.1%). During follow-up, 14.7% discontinued insulin therapy, 6.8% 
switched to a different regimen and 4.7% intensiﬁed therapy; adding mealtime insulin. 
Of the patients with a measurement during follow-up (n  3024), 17.3% achieved 
target HbA1c (7%). Clinical outcomes during follow-up [mean (SD)] were; HbA1c: 
8.3 (1.6)% and BMI: 30.7 (6.6) kg/m2. There was a slight increase in contact with 
HCPs during follow-up, mean 8.5 GP-surgery contacts. CONCLUSIONS: Patients 
had elevated HbA1c at insulin initiation, simple regimens were favoured; during a 
6 month follow-up a high proportion of patients failed to achieve glycaemic target.
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USING THE ECHO MODEL TO EXAMINE THE EFFECT OF AN 
EMPLOYER-SPONSORED PHARMACIST PROVIDED DIABETES MTM 
PROGRAM ON OUTCOMES
Pinto SL, Holl S
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OBJECTIVES: To examine economic, clinical, and humanistic outcomes of a pharma-
cist-provided Medication Therapy Management (MTM) program. METHODS: One 
year prospective, pre-post longitudinal study. Employees and dependents with a diag-
nosis of Type 2 diabetes were included. Pharmacists provided MTM services at 7 com-
munity pharmacies on ﬁve occasions in one year. Data collected: economic outcomes 
included costs and numbers of ER visits hospitalizations etc., clinical (A1C, blood 
pressure etc.), social (caffeine intake, alcohol consumption etc.), and process measures 
(podiatrist visits, eye exams, etc.), humanistic (patient’s quality of life (SF-36), medica-
tion adherence etc.). Data was analyzed using SPSS v. 16.0. Descriptive statistics, Wil-
coxon signed-rank tests and Friedman tests were used. Data analyses for the period 
between baseline and 6 month is given below. RESULTS: Ninety ﬁve patients enrolled 
at baseline. Mean A1c improved from 8.02 to 7.67 (p  0.20). Patients with uncon-
trolled A1cs at baseline saw a signiﬁcant decrease toward goal at six months. (p  0.01). 
Systolic blood pressure improved from 136.00 to 131.94 mmHg (p  0.221) and 
improved signiﬁcantly for patients with baseline SBP q 140 (p  0.000). Patients satis-
faction (p  0.000) and adherence improved from baseline (p  0.015). Quality of life 
scores improved but these changes were not signiﬁcant. Visits to specialty physicians 
improved signiﬁcantly from the previous year. On average, physician ofﬁce visits 
reduced from 10.2 to 8.36. Number and costs for ER visits decreased. Average hospi-
talization costs decreased from $ 22,252.24 to $ 17,016.19 and length of stay decreased 
by approximately 1.4 days. Total costs decreased by 62.69% (^$200,000). CONCLU-
SIONS: This MTM program has demonstrated improved outcomes and cost savings 
within the ﬁrst six months. Final results for the one year time point will be presented.
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OBJECTIVES: Diabetes disease management programmes (DDMP) were introduced 
in German statutory health insurance companies to improve medical care by funding 
health care based on evidence-based medical guidelines. The aim of this study was to 
compare persons with type 2 diabetes (DM2s) enrolled in a DDMP to those not 
enrolled regarding quality of health care and medical endpoints. METHODS: A popu-
lation based follow-up study was performed by the Cooperative Health Research in 
the Region of Augsburg (KORA) between 2006 and 2008. All DM2s received a 
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questionnaire regarding their medical care and self management. Medications (within 
the last 7 days), physical examination and laboratory tests were documented. DDMP 
participation was validated by the primary physician. Only DM2s with statutory 
health insurance and validated DDMP enrolment were included in the analysis (n  
166). Regression analyses adjusting for confounders (age, sex, education, diabetes 
duration and previous diabetes complications) were conducted. RESULTS: DDMP 
enrolees (n  89) reported medical examination of eyes and feet and medical advice 
regarding diet and physical activity more frequently (p  0.005), received antidiabetic 
and antihypertensive medications more often (p  0.05) and attended diabetes educa-
tion more frequently (p  0.005). DDMP enrolees measured their blood pressure more 
frequently (p  0.05). The groups did not differ regarding Hemoglobin A1c (HbA1c), 
but of 54 DM2s with values over 7%, only 3.6% of DDMP enrolees were receiving 
no antihyperglycemic medication whereas this was true for 38.5% of those not in 
DDMP. This difference remained signiﬁcant (p  0.0129) after adjustment for diabetes 
duration. CONCLUSIONS: According to our study, health care quality in DDMPs is 
improved. However, patient self-management of all diabetics must be improved.
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OBJECTIVES: Diabetes extracts a considerable economic toll on the US health care 
system. An analysis conducted in 2007, indicated that the economic burden of diabetes 
was $174 billion, with direct medical expenditures accounting for $116 billion. Origi-
nally published in 2006 and updated yearly, the American Diabetes Association 
(ADA)/European Association for the Study of Diabetes (EASD) Consensus Algorithm 
for the Initiation and Adjustment of Therapy, stands to guide health care practitioners 
in determining the most appropriate lifestyle and pharmacotherapeutic interventions 
for patients with Type 2 diabetes. We conducted an analysis to compare medication 
regimens from claims adjudicated by patients with Type 2 diabetes to treatment regi-
mens outlined in the ADA/EASD guidelines. METHODS: This retrospective claims 
analysis utilized data from the 2007 MarketScan® Commercial Claims and Encoun-
ters and the Medicare Supplemental and Coordination of Beneﬁts databases from 
Thomson Reuters. Medication regimens were evaluated for patients with Type-2 dia-
betes and at least one prescription claim for the fourth quarter of 2007. In order to 
be considered as part of a treatment regimen all medications must have had an over-
lapping 45 day period of utilization in the quarter. All identiﬁed medication regimens 
were compared to 2008 ADA/EASD consensus guidelines RESULTS: A total of 
191,535 patients were included in the analysis. In rank order, the top ﬁve treatment 
regimens by utilization frequency were as follows: biguanide monotherapy (27.9%), 
sulfonylurea monotherapy (14.53%), sulfonylureabiguanide combination therapy 
(12.01%), thiazolidinedione monotherapy (9.21%), thiazolidinedionebiguanide 
combination therapy (6.97%). CONCLUSIONS: As expected, following ADA/EASD 
guidelines, monotherapy with biguanide and a regimen of biguanidesulfoylurea were 
among the most frequently utilized regimens. The high degree of sulfonylurea mono-
therapy utilization may suggest that many patients may not tolerate monotherapy with 
biguanide. In all cases treatment must be individualized requiring the use of other 
agents to control blood glucose levels.
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ECONOMIC IMPACT OF COMPLIANCE AND PERSISTENCE TO 
TREATMENT WITH ANTIDIABETES MEDICATION IN T2DM— 
A SYSTEMATIC REVIEW
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OBJECTIVES: Suboptimal compliance and failure to persist with antidiabetes thera-
pies are of potential economic signiﬁcance. The present research aims to review the 
recent literature regarding the impact of poor compliance and persistence with antidi-
abetes medications on the cost of health care or its components for patients with type 
2 diabetes mellitus (T2DM). METHODS: Systematic literature search was conducted 
in pubmed for relevant articles published in the period between January 1, 2000 and 
April 30, 2009. Studies describing economic consequence of compliance and/or per-
sistence with pharmaceutical antidiabetes treatment were identiﬁed. RESULTS: Of 
449 articles corresponding to the primary search algorithm, 12 studies (all conducted 
in USA) fulﬁlled inclusion criteria regarding the economic impact of compliance and/or 
persistence with treatment on the overall cost of T2DM care or its components. 
Compliance was assessed via medication possession ratio (MPR) in 10 studies, and 
ranged from 0.52 to 0.93 depending on regimen. Persistence was assessed in one study. 
Mean total annual costs per patient having T2DM varied between the studies, ranging 
from $4,570 to $17,338. In 7 studies medication compliance was inversely associated 
with total health care costs, while in four other studies inverse associations between 
medication compliance and hospitalisation costs were reported. In one study increased 
adherence did not change overall health care costs. CONCLUSIONS: Improved com-
pliance can lead to reductions of the total health care costs in T2DM, mainly through 
decrease in hospitalisations. Studies assessing economic impact of persistence with 
pharmacotherapy in T2DM are limited, and studies investigating cost consequences 
of compliance are predominantly using MPR as a measure of compliance. Further 
research is needed in countries other than USA to assess impact of compliance and 
persistence to pharmacotherapy on T2DM costs in country-speciﬁc settings. Research-
ers should follow deﬁnitions of compliance and persistence proposed by the ISPOR 
Medication Compliance and Persistence Special Interest Group.
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THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER 
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OBJECTIVES: Meta-Analyses of oral hypoglycemic agents (OHA) revealed that Rosi-
glitazone (Rosi) increased the risk of Myocardial Infarction (MI) and Heart Failure 
(HF), and Pioglitazone (Pio) increased the risk of HF and decreased the risk of MI. 
The objective of this research is to compare OHA utilization patterns, before and after 
these publications. METHODS: CareFirst BlueCross BlueShield’s claims were ana-
lyzed for patients continuously enrolled from January 2005 through December 2007 
who started on mono-Rosi or mono-Pio. The “pre-publication” period (November 1, 
2006—March 31, 2007) was compared to the “post-publication” period (July 1, 
2007—December 1, 2007) using a difference-in-difference approach. Multinomial 
logistic regression (MLR) explored discontinuation; continuation with monotherapy 
or adding another drug; and switching after adjusting for gender, age, type of insur-
ance, history of MI or HF and risk factors for MI and HF. RESULTS: The number 
of monotherapy Rosi users decreased from the pre (N  368, 5.94%) to post (N  
170, 2.87%) period, while monotherapy Pio use was stable across the two periods. 
The proportion who switched from Rosi to non-Rosi drugs changed from 2.17% in 
pre-period to 5.88% in post period. Adjusted relative risk was 2.66 (95 % CI 1.0569, 
6.7689). Pio to non-pio drugs switching was 1.48% in pre-period and 1.16% in post-
period (relative risk not signiﬁcant). Therefore, the impact of the new studies on Rosi 
users to switch to non-Rosi drug, relative to Pio users before and after the publication 
was 3.6189 (90%CI 1.051, 12.457). CONCLUSIONS: Consistent with prior research, 
the utilization of Rosi declined by more than half in the post-period. Additionally, 
Rosi users were three times more likely to switch to a non-Rosi drug in the post period, 
relative to Pio users. Therefore, our results show that the publications about safety 
risks had differential impact between the two drugs within therapeutic class.
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A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH 
INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME 
INSULIN TO A BASAL REGIMEN
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OBJECTIVES: Following a commitment to an intensive glucose-lowering regimen that 
includes mealtime insulin is eventually required by patients taking basal insulin to 
maintain good glycemic control. The objective of this study was to characterize and 
examine factors associated with persistence to mealtime insulin. METHODS: Patients 
with diagnosed type-2 diabetes, with at least 2 prescriptions for mealtime insulin 
(index medication) between July 2001 and Sept 2006, were identiﬁed from a US 
managed care claims database. Patients were required to have 6 months pre- and 15 
months post-index continuous eligibility and at least 2 basal insulin prescriptions in 
pre-index period. Persistence measure #1 was deﬁned by the absence of prescription 
gap of greater than 90 days, with non-persistence effective the date of the last prescrip-
tion prior to the 90 day gap. Persistence measure #2 required one prescription per 
quarter to be persistent at 12 months; persistence at 3 and 6 months were deﬁned 
similarly. Logistic regression models were used to examine predictors of persistence 
to mealtime insulin at 12 months. RESULTS: Patients adding mealtime insulin to their 
basal regimen (n  4,752; 51% male, mean age  60.3 years) mostly used insulin 
analogs (60%) and vial/syringe (87%). The median number of mealtime insulin pre-
scription claims ﬁlled per patient was 2, 3 and 4 at 3, 6 and 12 months respectively, 
with the median time between reﬁlls being 75.5 days. Persistence to mealtime insulin 
was 40.7%, 30.2% and 19.1% using measure #1 and 74.3%, 55.3% and 42.2% using 
measure # 2 at 3, 6 and 12 months, respectively. Patients initiating with human insulin 
were less likely to be persistent across measures of persistence (OR  0.80, p  0.01). 
Additional predictors of persistence at 12 months included age, copayment, mental 
health comorbidity and polypharmacy. CONCLUSIONS: Persistence to insulin 
therapy is poorer than one would anticipate and is signiﬁcantly lower for human 
insulin compared to analogs.
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REAL-LIFE PRESCRIPTION PATTERNS SHOW FEWER TREATMENT 
CHANGES WITH BASAL INSULIN ANALOGS COMPARED TO NPH IN 
TYPE 2 DIABETES IN THE NETHERLANDS
Thomsen TL1, Heintjes EM2, Penning-van Beest FJA2, Christensen TE1, Herings RM2
1Novo Nordisk A/S, Virum, Denmark, 2PHARMO Institute, Utrecht, The Netherlands
OBJECTIVES: Using the Dutch PHARMO database, the aim was to 1) determine the 
percentage of type 2 diabetes (T2D) patients starting on long-acting insulin analogues 
versus NPH; 2) compare previous insulin experience in patients; and 3) establish the 
number of patients changing treatment within one year. METHODS: The PHARMO 
database includes community pharmacy drug dispensing and hospitalisation records 
